Tuesday, 10 December 2019

Korea approves Opdivo-Yervoy for renal cell carcinoma treatment

10 September 2018 | News

The approval is based on a clinical trial called CheckMate-214.

Image credit- stockvault.net

Image credit- stockvault.net

The Korean government has approved Ono Pharma Korea and Bristol-Myers Squibb Korea to sell Opdivo (nivolumab)-Yervoy (ipilimumab) combination therapy as the first-line immunotherapy to treat renal cell carcinoma (RCC).

The approval is based on a clinical trial called CheckMate-214, which evaluated the Opdivo-Yervoy combo in patients with moderate- and high-risk advanced RCC who did not have any treatment experience.

The study showed the combined therapy proved effective in achieving improved survival compared to sunitinib (under trade name Sutent by Pfizer), regardless of PD-L1 (programmed death-ligand 1) expression.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Podcast

 

Survey Box

Is APAC region emerging as a leader in assistive technologies?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls